Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 442

Similar articles for PubMed (Select 19407449)

1.

Levodopa: past, present, and future.

Hauser RA.

Eur Neurol. 2009;62(1):1-8. doi: 10.1159/000215875. Epub 2008 Sep 9. Review.

2.

COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications?

Olanow CW, Stocchi F.

Neurology. 2004 Jan 13;62(1 Suppl 1):S72-81. Review.

PMID:
14718683
3.

New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease.

Bonifati V, Meco G.

Pharmacol Ther. 1999 Jan;81(1):1-36. Review.

PMID:
10051176
4.
5.

L-dopa therapy for Parkinson's disease: past, present, and future.

Nagatsua T, Sawadab M.

Parkinsonism Relat Disord. 2009 Jan;15 Suppl 1:S3-8. doi: 10.1016/S1353-8020(09)70004-5. Review.

PMID:
19131039
6.

Treatment of levodopa-induced motor complications.

Stocchi F, Tagliati M, Olanow CW.

Mov Disord. 2008;23 Suppl 3:S599-612. doi: 10.1002/mds.22052. Review.

PMID:
18781681
7.

History of levodopa and dopamine agonists in Parkinson's disease treatment.

Tolosa E, Martí MJ, Valldeoriola F, Molinuevo JL.

Neurology. 1998 Jun;50(6 Suppl 6):S2-10; discussion S44-8.

PMID:
9633679
8.

Levodopa-related wearing-off in Parkinson's disease: identification and management.

Pahwa R, Lyons KE.

Curr Med Res Opin. 2009 Apr;25(4):841-9. doi: 10.1185/03007990902779319 . Review.

PMID:
19228103
9.
10.

Maximizing the benefit:risk ratio of levodopa therapy in Parkinson's disease.

Gottwald MD.

Pharmacotherapy. 1999 Nov;19(11 Pt 2):162S-8S.

PMID:
10555944
11.

Levodopa/dopamine replacement strategies in Parkinson's disease--future directions.

Olanow CW.

Mov Disord. 2008;23 Suppl 3:S613-22. doi: 10.1002/mds.22061. Review.

PMID:
18781663
12.
13.

Current management of motor fluctuations in patients with advanced Parkinson's disease treated chronically with levodopa.

Melamed E, Zoldan J, Galili-Mosberg R, Ziv I, Djaldetti R.

J Neural Transm Suppl. 1999;56:173-83. Review.

PMID:
10370911
14.

Pharmacokinetic-pharmacodynamic interaction between nebicapone, a novel catechol-o-methyltransferase inhibitor, and controlled-release levodopa/carbidopa 200 mg/50 mg : randomized, double-blind, placebo-controlled, crossover study in healthy subjects.

Vaz-da-Silva M, Loureiro AI, Nunes T, Lopes C, Rocha J, Machado R, Costa R, Torrão L, Falcão A, Wright L, Almeida L, Soares-da-Silva P.

Drugs R D. 2008;9(6):435-46. doi: 10.2165/0126839-200809060-00006.

PMID:
18989992
15.

Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.

Nyholm D.

Clin Pharmacokinet. 2006;45(2):109-36. Review.

PMID:
16485914
16.

Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease.

Olanow CW, Obeso JA, Stocchi F.

Nat Clin Pract Neurol. 2006 Jul;2(7):382-92. Review.

PMID:
16932589
17.

COMT inhibitors in Parkinson's disease.

Rivest J, Barclay CL, Suchowersky O.

Can J Neurol Sci. 1999 Aug;26 Suppl 2:S34-8. Review.

PMID:
10451758
18.

Levodopa in Parkinson's disease: from the past to the future.

Pezzoli G, Zini M.

Expert Opin Pharmacother. 2010 Mar;11(4):627-35. doi: 10.1517/14656561003598919. Review.

PMID:
20163273
19.

Optimizing pharmacotherapy: strategies to manage the wearing-off phenomenon.

Tse W.

J Am Med Dir Assoc. 2006 Sep;7(7 Suppl 2):12-7. Review.

PMID:
17948614
20.

Off spells and dyskinesias: pharmacologic management of motor complications.

Khan TS.

Cleve Clin J Med. 2012 Jul;79 Suppl 2:S8-13. doi: 10.3949/ccjm.79.s2a.02. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk